Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

References

• AndesDDiekemaDJPfallerMA2008aIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis modelAntimicrob Agents Chemother525395018070979
   PubMed Web of Science ®Google Scholar
• AndesDRDiekemaDJPfallerMA2008bIn vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. g1abrata in a neutropenic murine candidiasis modelAntimicrob Agents Chemother52349750318625768
   PubMed Web of Science ®Google Scholar
• AntachopoulosCMeletiadisJSeinT2008Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated Aspergillus ConidiaAntimicrob Agents Chemother52321817938191
   PubMed Web of Science ®Google Scholar
• ArikanSLozano-ChiuMPaetznickV2001In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolatesAntimicrob Agents Chemother453273011120990
   PubMed Web of Science ®Google Scholar
• ArikanSYurdakulPHascelikG2003Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus sppAntimicrob Agents Chemother472640312878531
   PubMed Web of Science ®Google Scholar
• BaddleyJWStroudTPSalzmanD2001Invasive mold infections in allogeneic bone marrow transplant recipientsClin Infect Dis3213192411303267
   PubMed Web of Science ®Google Scholar
• BalashovSVParkSPerlinDS2006Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1Antimicrob Agents Chemother5020586316723566
   PubMed Web of Science ®Google Scholar
• BeauvaisABruneauJMMolPC2001Glucan synthase complex of Aspergillus fumigatusJ Bacteriol1832273911244067
   PubMed Web of Science ®Google Scholar
• BodeyGPMardaniMHannaHA2002The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancerAm J Med112380511904112
   PubMed Web of Science ®Google Scholar
• BowmanJCHicksPSKurtzMB2002The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitroAntimicrob Agents Chemother4630011212183260
   PubMed Web of Science ®Google Scholar
• BozzaSGazianoRSprecaA2002Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungusJ Immunol16813627111801677
   PubMed Web of Science ®Google Scholar
• BozzaSPerruccioKMontagnoliC2003A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantationBlood10238071412791648
   PubMed Web of Science ®Google Scholar
• BrownGD2006Dectin-1: a signalling non-TLR pattern-recognition receptorNat Rev Immunol6334316341139
   PubMed Web of Science ®Google Scholar
• Cancidas2005Cancidas Package InsertMerck and Co., Inc.Whitehouse Station, NJ, USA
   Google Scholar
• ChamilosGLewisREAlbertN2007Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differencesAntimicrob Agents Chemother512257917438060
   PubMed Web of Science ®Google Scholar
• ChillerTFarrokhshadKBrummerE2000Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatusAntimicrob Agents Chemother443302511083631
   PubMed Web of Science ®Google Scholar
• ClearyJDGarcia-EffronGChapmanSW2008Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatmentAntimicrob Agents Chemother522263518378714
   PubMed Web of Science ®Google Scholar
• ClemonsKVEspirituMParmarR2005Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosisAntimicrob Agents Chemother4948677516304147
   PubMed Web of Science ®Google Scholar
• CornelyOAMaertensJWinstonDJ2007Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropeniaN Engl J Med3563485917251531
   PubMed Web of Science ®Google Scholar
• CotaJCardenMGraybillJR2006In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibilityAntimicrob Agents Chemother503926816940061
   PubMed Web of Science ®Google Scholar
• CotaJMGrabinskiJLTalbertRL2008Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofunginAntimicrob Agents Chemother521144618086838
   PubMed Web of Science ®Google Scholar
• De WetNLlanos-CuentasASuleimanJ2004A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patientsClin Infect Dis39842915472817
   PubMed Web of Science ®Google Scholar
• De WetNTBesterAJViljoenJJ2005A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasisAliment Pharmacol Ther2189990715801925
   PubMed Web of Science ®Google Scholar
• DenningDWMarrKALauWM2006Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosisJ Infect533374916678903
   PubMed Web of Science ®Google Scholar
• DomerJE1971Monosaccharide and chitin content of cell walls of Histoplasma capsulatum and Blastomyces dermatitidisJ Bacteriol10787075095293
   PubMed Web of Science ®Google Scholar
• DouglasCMD’ippolitoJASheiGJ1997Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitorsAntimicrob Agents Chemother41247199371352
   PubMed Web of Science ®Google Scholar
• DouglasCMMarrinanJALiW1994A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthaseJ Bacteriol1765686968083161
   PubMed Web of Science ®Google Scholar
• ErnstEJRolingEEPetzoldCR2002In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studiesAntimicrob Agents Chemother4638465312435687
   PubMed Web of Science ®Google Scholar
• Espinel-IngroffA2003In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literatureRev Iberoam Micol201213615456349
   PubMedGoogle Scholar
• Garcia-EffronGKatiyarSKParkS2008aA naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibilityAntimicrob Agents Chemother5223051218443110
   PubMed Web of Science ®Google Scholar
• Garcia-EffronGKontoyiannisDPLewisRE2008bCaspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignanciesAntimicrob Agents Chemother524181318794386
   PubMed Web of Science ®Google Scholar
• Garcia-VidalCUptonAKirbyKA2008Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantationClin Infect Dis4710415018781877
   PubMed Web of Science ®Google Scholar
• GoodmanDPamerEJakubowskiA2002Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetateClin Infect Dis35E35612115115
   PubMed Web of Science ®Google Scholar
• GraybillJRNajvarLKMontalboEM1998Treatment of histoplasmosis with MK-991 (L-743,872)Antimicrob Agents Chemother4215139449276
   PubMed Web of Science ®Google Scholar
• GumboTDrusanoGLLiuW2007Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaAntimicrob Agents Chemother519687417194830
   PubMed Web of Science ®Google Scholar
• GumboTHiemenzJMaL2008Population pharmacokinetics of micafungin in adult patientsDiagn Microbiol Infect Dis603293118024052
   PubMed Web of Science ®Google Scholar
• HakkiMStaabJFMarrKA2006Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapyAntimicrob Agents Chemother502522416801435
   PubMed Web of Science ®Google Scholar
• HebertMFBloughDKTownsendRW2005aConcomitant tacrolimus and micafungin pharmacokinetics in healthy volunteersJ Clin Pharmacol4510182416100295
   PubMed Web of Science ®Google Scholar
• HebertMFSmithHEMarburyTC2005bPharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunctionJ Clin Pharmacol4511455216172179
   PubMed Web of Science ®Google Scholar
• HebertMFTownsendRWAustinS2005cConcomitant cyclosporine and micafungin pharmacokinetics in healthy volunteersJ Clin Pharmacol459546016027407
   PubMed Web of Science ®Google Scholar
• HeresiGPGerstmannDRReedMD2006The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infantsPediatr Infect Dis J251110517133155
   PubMed Web of Science ®Google Scholar
• HeynKTredupASalvenmoserS2005Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solaniAntimicrob Agents Chemother495157916304192
   PubMed Web of Science ®Google Scholar
• HiemenzJCagnoniPSimpsonD2005Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplantAntimicrob Agents Chemother491331615793107
   PubMed Web of Science ®Google Scholar
• HohlTMFeldmesserMPerlinDS2008Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposureJ Infect Dis1981768518500928
   PubMed Web of Science ®Google Scholar
• IchiyasuHYamamuraAHondaM2006[Successful treatment by voliconazole for pulmonary and adductor magnus muscle aspergillosis induced by immunosuppressive therapy for hypersensitivity pneumonia]Nihon Kokyuki Gakkai Zasshi447546017087345
   PubMedGoogle Scholar
• IkedaFWakaiYMatsumotoS2000Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosisAntimicrob Agents Chemother44614810681327
   PubMed Web of Science ®Google Scholar
• KahnJNGarcia-EffronGHsuMJ2007Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthaseAntimicrob Agents Chemother511876817325225
   PubMed Web of Science ®Google Scholar
• KanetsunaFCarbonellLM1971Cell wall composition of the yeastlike and mycelial forms of Blastomyces dermatitidisJ Bacteriol10694685557599
   PubMed Web of Science ®Google Scholar
• KanetsunaFCarbonellLMAzumaI1972Biochemical studies on the thermal dimorphism of Paracoccidioides brasiliensisJ Bacteriol110208185018021
   PubMed Web of Science ®Google Scholar
• KeirnsJSawamotoTHolumM2007Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsAntimicrob Agents Chemother517879017116670
   PubMed Web of Science ®Google Scholar
• KohlerSWheatLJConnollyP2000Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine modelAntimicrob Agents Chemother441850410858342
   PubMed Web of Science ®Google Scholar
• KonishiHSudoMSumiM2005Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failureBiol Pharm Bull28556915744091
   PubMed Web of Science ®Google Scholar
• KontoyiannisDPHachemRLewisRE2003Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesCancer98292912872348
   PubMed Web of Science ®Google Scholar
• KontoyiannisDPRatanatharathornVYoungJA2008Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosisTranspl Infect DisDOI: 10.1111/j.1399-3062.2008.00349.x
   Web of Science ®Google Scholar
• KrauseDSSimjeeAEVan RensburgC2004A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasisClin Infect Dis39770515472806
   PubMed Web of Science ®Google Scholar
• KullbergBJSobelJDRuhnkeM2005Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialLancet36614354216243088
   PubMed Web of Science ®Google Scholar
• KurtzMBHeathIBMarrinanJ1994Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthaseAntimicrob Agents Chemother38148097979276
   PubMed Web of Science ®Google Scholar
• KuseERChetchotisakdPDa CunhaCA2007Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialLancet36915192717482982
   PubMed Web of Science ®Google Scholar
• LamarisGALewisREChamilosG2008Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphaeJ Infect Dis1981869218500936
   PubMed Web of Science ®Google Scholar
• LaverdiereMLalondeRGBarilJG2006Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitisJ Antimicrob Chemother57705816464893
   PubMed Web of Science ®Google Scholar
• LeeJWSeibelNLAmanteaM1992Safety and pharmacokinetics of fluconazole in children with neoplastic diseasesJ Pediatr120987931593362
   PubMed Web of Science ®Google Scholar
• LewisREAlbertNDKontoyiannisDP2008aComparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosisJ Antimicrob Chemother611140418305201
   PubMed Web of Science ®Google Scholar
• LewisREAlbertNDKontoyiannisDP2008bEfficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosisAntimicrob Agents Chemother5241788018725439
   PubMed Web of Science ®Google Scholar
• LinSJSchranzJTeutschSM2001Aspergillosis case-fatality rate: systematic review of the literatureClin Infect Dis323586611170942
   PubMed Web of Science ®Google Scholar
• MaertensJRaadIPetrikkosG2004Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapyClin Infect Dis3915637115578352
   PubMed Web of Science ®Google Scholar
• MaesakiSHossainMAMiyazakiY2000Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in miceAntimicrob Agents Chemother4417283010817741
   PubMed Web of Science ®Google Scholar
• MakiKMatsumotoSWatabeE2008Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compoundsMicrobiol Immunol523839118667037
   PubMed Web of Science ®Google Scholar
• MalaniAHmoudJChiuL2005Candida glabrata fungemia: experience in a tertiary care centerClin Infect Dis419758116142662
   PubMed Web of Science ®Google Scholar
• MarrKA2008Fungal infections in hematopoietic stem cell transplant recipientsMed Mycol4629330218415836
   PubMed Web of Science ®Google Scholar
• MarrKACarterRACrippaF2002Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipientsClin Infect Dis349091711880955
   PubMed Web of Science ®Google Scholar
• MarrKACrippaFLeisenringW2004Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplantsBlood10315273314525770
   PubMed Web of Science ®Google Scholar
• MatsueKUryuHKosekiM2006Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafunginClin Infect Dis42753716477548
   PubMed Web of Science ®Google Scholar
• MesserSADiekemaDJBoykenL2006Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida sppJ Clin Microbiol44324616455878
   PubMed Web of Science ®Google Scholar
• MochizukiNAibikiMMatsumotoY200646th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstr M-1598San Francisco, CA
   Google Scholar
• Mora-DuarteJBettsRRotsteinC2002Comparison of caspofungin and amphotericin B for invasive candidiasisN Engl J Med3472020912490683
   PubMed Web of Science ®Google Scholar
• Mycamine2008Mycamine Package InsertAstellas Pharma, US, Inc
   Google Scholar
• NakagawaYIchiiYSaekiY2007Plasma concentration of micafungin in patients with hematologic malignanciesJ Infect Chemother13394517334728
   PubMedGoogle Scholar
• NakaiTUnoJIkedaF2003In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial formsAntimicrob Agents Chemother4713768112654673
   PubMed Web of Science ®Google Scholar
• OddsFCMotylMAndradeR2004Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus speciesJ Clin Microbiol4234758215297486
   PubMed Web of Science ®Google Scholar
• OsherovNMayGSAlbertND2002Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiaeAntimicrob Agents Chemother462462912121919
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLKontoyiannisDRaffalliJ2005International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemiaEur J Clin Microbiol Infect Dis246546116261306
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLRexJHPappasPG2003Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United StatesAntimicrob Agents Chemother4731495414506023
   PubMed Web of Science ®Google Scholar
• PaderuPGarcia-EffronGBalashovS2007Serum differentially alters the antifungal properties of echinocandin drugsAntimicrob Agents Chemother512253617420211
   PubMed Web of Science ®Google Scholar
• PappasPGRotsteinCMBettsRF2007Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasisClin Infect Dis458839317806055
   PubMed Web of Science ®Google Scholar
• ParkSKellyRKahnJN2005Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolatesAntimicrob Agents Chemother4932647316048935
   PubMed Web of Science ®Google Scholar
• PelletierRAlarieILagaceR2005Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literatureMed Mycol435596416320498
   PubMed Web of Science ®Google Scholar
• PetraitisVPetraitieneRGrollAH2002Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbitsAntimicrob Agents Chemother4618576912019101
   PubMed Web of Science ®Google Scholar
• PfallerMRileyJKoernerT1989Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicansEur J Clin Microbiol Infect Dis81067702695329
   PubMed Web of Science ®Google Scholar
• PfallerMABoykenLHollisRJ2008aIn vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillanceJ Clin Microbiol46150618032613
   PubMed Web of Science ®Google Scholar
• PfallerMABoykenLHollisRJ2006In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillanceJ Clin Microbiol44760316517851
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJ2007Epidemiology of invasive candidiasis: a persistent public health problemClin Microbiol Rev201336317223626
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJOstrosky-ZeichnerL2008bCorrelation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpointsJ Clin Microbiol462620918579718
   PubMed Web of Science ®Google Scholar
• Queiroz-TellesFBerezinELevergerG2008Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trialPediatr Infect Dis J27820618679151
   PubMed Web of Science ®Google Scholar
• RamageGVandewalleKBachmannSP2002In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studiesAntimicrob Agents Chemother463634612384379
   PubMed Web of Science ®Google Scholar
• ReboliACRotsteinCPappasPG2007Anidulafungin versus fluconazole for invasive candidiasisN Engl J Med35624728217568028
   PubMed Web of Science ®Google Scholar
• RexJHBennettJESugarAM1994A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National InstituteN Engl J Med3311325307935701
   PubMed Web of Science ®Google Scholar
• SakaedaTIwakiKKakumotoM2005Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugsJ Pharm Pharmacol577596415969931
   PubMed Web of Science ®Google Scholar
• SeibelNLSchwartzCArrietaA2005Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patientsAntimicrob Agents Chemother4933172416048942
   PubMed Web of Science ®Google Scholar
• SirohiBPowlesRLChopraR2006A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantationBone Marrow Transplant38475116715107
   PubMed Web of Science ®Google Scholar
• StevensDAEspirituMParmarR2004Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrationsAntimicrob Agents Chemother4834071115328104
   PubMed Web of Science ®Google Scholar
• StevensDAIchinomiyaMKoshiY2006Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin:evidence for beta-1,6-glucan synthesis inhibition by caspofunginAntimicrob Agents Chemother503160116940118
   PubMed Web of Science ®Google Scholar
• TawaraSIkedaFMakiK2000In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungiAntimicrob Agents Chemother44576210602723
   PubMed Web of Science ®Google Scholar
• TaylorPRTsoniSVWillmentJA2007Dectin-1 is required for beta-glucan recognition and control of fungal infectionNat Immunol831817159984
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdWiederholdNPVallorAC2008Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infectionAntimicrob Agents Chemother523783518676885
   PubMed Web of Science ®Google Scholar
• UllmannAJLiptonJHVesoleDH2007Posaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseN Engl J Med3563354717251530
   PubMed Web of Science ®Google Scholar
• Van BurikJARatanatharathornVStepanDE2004Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantationClin Infect Dis3914071615546073
   PubMed Web of Science ®Google Scholar
• VillanuevaAGotuzzoEArathoonEG2002A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasisAm J Med113294912361815
   PubMed Web of Science ®Google Scholar
• WaldALeisenringWVan BurikJA1997Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantationJ Infect Dis1751459669180187
   PubMed Web of Science ®Google Scholar
• WalshTJAdamsonPCSeibelNL2005Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescentsAntimicrob Agents Chemother4945364516251293
   PubMed Web of Science ®Google Scholar
• WalshTJKarlssonMODriscollT2004Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administrationAntimicrob Agents Chemother4821667215155217
   PubMed Web of Science ®Google Scholar
• WatabeENakaiTMatsumotoS2003Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viabilityAntimicrob Agents Chemother471995812760883
   PubMed Web of Science ®Google Scholar
• WiederholdNPKontoyiannisDPPrinceRA2005Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathwaysAntimicrob Agents Chemother495146816304189
   PubMed Web of Science ®Google Scholar
• WiederholdNPLewisRE2003The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacyExpert Opin Investig Drugs12131333
   PubMed Web of Science ®Google Scholar
• WiederholdNPNajvarLKBocanegraR2007In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of seraAntimicrob Agents Chemother5116162017307976
   PubMed Web of Science ®Google Scholar
• WinstonDJMaziarzRTChandrasekarPH2003Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trialAnn Intern Med1387051312729424
   PubMed Web of Science ®Google Scholar
• WisplinghoffHBischoffTTallentSM2004Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance studyClin Infect Dis393091715306996
   PubMed Web of Science ®Google Scholar